TILT Biotherapeutics Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 17
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $6.17M
Latest Deal Amount
  • Investors
  • 7

TILT Biotherapeutics General Information

Description

Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. The company's platform involves utilization of oncolytic viruses for enhancement of tumor cell therapy and will be used in tumor infiltrating lymphocyte, chimeric antigen receptor and checkpoint, enabling researchers to inhibit antibody therapy for solid tumors so as to achieve similar results.

Contact Information

Website
www.tiltbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • Haartmaninkatu 3
  • 4th floor, C-wing
  • 00290 Helsinki
  • Finland

TILT Biotherapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TILT Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 16-Jun-2020 $6.17M 000.00 000.00 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series A) 04-Jun-2018 Cancelled Clinical Trials - Phase 1
4. Grant 04-Jun-2018 00.000 00.00 Completed Clinical Trials - Phase 1
3. Seed Round 14-Dec-2016 00.000 00.00 Completed Pre-Clinical Trials
2. Seed Round 30-Sep-2015 $3.48M $5.32M 00.000 Completed Pre-Clinical Trials
1. Seed Round 01-Aug-2013 $1.83M $1.83M 00.000 Completed Pre-Clinical Trials
To view TILT Biotherapeutics’s complete valuation and funding history, request access »

TILT Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.00 00.00 00 00.00 00.000
Ordinary 00,000 000.0 000.0 00 000.0 0.000
Series A 212,713 $17.38 $17.38 1x $17.38 1.2%
Series A 202,090 $4.95 $4.95 1x $4.95 1.14%
To view TILT Biotherapeutics’s complete cap table history, request access »

TILT Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvi
Biotechnology
Helsinki, Finland
17 As of 2021
000.00
00.00 0000-00-00
0000000000 0 000.00

0000 000

aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cill
0000000000000
Santa Monica, CA
000 As of 0000
00000
000 0000-00-00
000000&0 00000

00000 00

ugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia dese
0000000000000
Waltham, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TILT Biotherapeutics Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
00000 000000000000 Formerly VC-backed Waltham, MA 00 00000 00000000 00000
000000000 Formerly VC-backed Woburn, MA 000 00000 00000000 00000
0000000 Venture Capital-Backed Houston, TX 00 000.00 000000000 - 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 38 competitors. Get the full list »

TILT Biotherapeutics Executive Team (4)

Name Title Board Seat Contact Info
Akseli Hemminki MD Founder, Chief Executive Officer & Board Member
Aino Kalervo Head of Business Management & Chief Business Officer
Tuija Keinonen Ph.D Chief Regulatory Officer and Board Member
Kari Varkila Ph.D Chief Medical Officer
To view TILT Biotherapeutics’s complete executive team members history, request access »

TILT Biotherapeutics Board Members (8)

Name Representing Role Since
Akseli Hemminki MD TILT Biotherapeutics Founder, Chief Executive Officer & Board Member 000 0000
Arto Linnervuo Roschier Legal Advisor & Board Member 000 0000
Jyrki Liljeroos Self Chairman & Senior Business Advisor 000 0000
Kenneth Forssell Self Board Member and Strategy and Commercial Advisor 000 0000
Pekka Mattila Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

TILT Biotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TILT Biotherapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
PowerBank Ventures Venture Capital Minority 000 0000 000000 0
Horizon 2020 Government Minority 000 0000 000000 0
Business Finland Accelerator/Incubator Minority 000 0000 000000 0
Keksintösäätiö Not-For-Profit Venture Capital Minority 000 0000 000000 0
Les Business Angels des Grandes Écoles Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »